IN THE SPOTLIGHT

How One Young Adult With Stage 4 Lung Cancer Is Beating the Odds

How One Young Adult With Stage 4 Lung Cancer Is Beating the Odds

Zongertinib Displays Early Activity and Tolerability in HER2-Mutated Solid Tumors

Zongertinib Displays Early Activity and Tolerability in HER2-Mutated Solid Tumors

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

Monitoring Patients With RET-Positive NSCLC

Monitoring Patients With RET-Positive NSCLC

FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC

FDA Accepts New Drug Application For Taletrectinib in ROS1+ NSCLC

China NMPA approves Innovent Biologics’ Dovbleron to treat ROS1-positive non-small cell lung cancer

China NMPA approves Innovent Biologics’ Dovbleron to treat ROS1-positive non-small cell lung cancer

Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC

Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC